Yazar "Gullu, Murat" seçeneğine göre listele

Listeleniyor 1 - 3 / 3
  • Küçük Resim
    Öğe
    Frequency of Metabolic Syndrome among Hemodialysis Patients According to NCEP-ATP III and IDF Definitions
    (Taylor & Francis Ltd, 2009) Ucar, Edip; Huzmeli, Can; Guven, Oguz; Savas, Nazan; Gullu, Murat; Asilyoruk, Sema; Kuvandik, Ceren
    Objective. Patients with chronic renal failure (CRF) have an increased risk of death from cardiovascular diseases. The metabolic syndrome is a common risk factor for cardiovascular diseases. In the present study, it was aimed to evaluate the frequency of metabolic syndrome using the National Cholesterol Education Program Adults Treatment Panel III (NCEP-ATP III) and the International Diabetes Federation (IDF) definitions in patients with end-stage CRF undergoing hemodialysis (HD). Materials and Methods. A total of 222 cases undergoing HD were enrolled in the study. After obtaining medical history and physical examination, blood samples were collected from each patient for the measurements of fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides. Results. Among HD patients evaluated according to both IDF and NCEP-ATP III definitions, the diagnosis of metabolic syndrome was confirmed by IDF in 56.5% of those fulfilling the criteria for NCEP-ATP III. Similarly, 86% of the undiagnosed patients according to NCEP-ATP III were confirmed by IDF definitions. The sensitivity and positive predictive value of NCEP-ATP III for metabolic syndrome were 81.25% and 64.8%, respectively. The area under the Receiver Operating Characteristic (ROC) curve for NECP-ATP III and IDF was 0.730. False-positive rate and probability ratio for NECP-ATP III were 0.352 and 2.49, respectively. In other words, among the patients who were diagnosed with metabolic syndrome according to NCEP-ATP III definitions, the proportion of subjects whose diagnosis was confirmed by IDF definitions was 2.49-fold higher than those with unconfirmed diagnosis. Conclusion. It is logical to evaluate patients with CRF for metabolic syndrome and cardiovascular risk factors at the time of diagnosis and regularly thereafter due to the high ratio of metabolic syndrome in this population.
  • Küçük Resim
    Öğe
    HEPATITIS E VIRUS SEROPOSITIVITY IN HEMODIALYSIS PATIENTS IN HATAY PROVINCE, TURKEY
    (Ankara Microbiology Soc, 2009) Ucar, Edip; Cetin, Meryem; Kuvandik, Ceren; Helvaci, Mehmet Rami; Gullu, Murat; Huzmeli, Can
    Hepatitis E virus (HEV) which is mainly transmitted through faecal-oral route, can also be transmitted via parenteral and vertical route. Recent studies suggest zoonotic nature of the virus. The last studies done in Turkey indicate increasing frequency of HEV infection. This study was conducted to determine the rate of anti-HEV seropositivity among patients with terminal stage renal failure undergoing hemodialysis. A total of 92 patients (54 male, 38 female; age range: 22-71 years, mean age: 55 +/- 11 years) who had undergone hemodialysis for a mean period of 66 +/- 18 months, were included to the study. HEV antibodies were analyzed using anti-HEV IgG enzyme immunoassay (ELISA, Dia.Pro Diagnostic Bioprobes, Italy). In order to study the relationship of anti-HEV positivity between hepatitis C virus and hepatitis B virus infections, anti-HCV antibody and HBsAg were also considered. Mean age, duration of hemodialysis, platelet, serum albumin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, blood transfusion history were the other evaluated parameters. Anti-HEV IgG positivity was detected in 19 (20.6%) patients, while 7 (7.6%) had anti-HCV positivity and 4 (4.3%) had HBsAg positivity. No statistically significant relation was determined between anti-HEV IgG positive and negative patients in terms of hemodialysis duration, blood transfusion, other laboratory findings and anti-HCV and HBsAg positivity (p> 0.05). While the anti-HEV seropositivity rate (20.6%) determined in this study was higher than the rates determined in the same group of patients in the western part of the country (10-16%), the rate, vas similar to the rates reported from the southeastern part (23%) of Turkey. It can be concluded that screening of patients before or during hemodialysis in terms of anti-HEV antibodies, seems to be of crucial importance in order to establish necessary precautions to prevent parenteral and/or nosocomial transmission of HEV.
  • Küçük Resim
    Öğe
    Prognostic Value of Preoperative CEA, CA 19-9, CA 72-4, and AFP Levels in Gastric Cancer
    (Springer, 2008) Ucar, Edip; Semerci, Ersan; Ustun, Hasan; Yetim, Tugba; Huzmeli, Can; Gullu, Murat
    Introduction: Recent research has suggested that serum tumor markers can give valuable prognostic information in gastric cancer. In this study, we examined the relationship between preoperative serum carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9, CA 72-4, and alfa fetoprotein (AFP) levels on clinicopathologic significance in gastric cancer patients. Methods: Preoperative plasma levels of CEA, CA 19-9, CA 72-4, and AFP were retrospectively examined in 95 patients who underwent surgical resection for gastric cancer, and the prognostic value of the tumour markers were estimated. Results: The percentage of CA 19-9, CA 72-4, CEA, and AFP-positive cases were 41%, 32.6%, 24.2%, and 8.4%, respectively. CEA was more frequently positive in the patients with liver metastases (P=0.02). CA 19-9 was more frequently positive in patients with lymph node (P=0.005), peritoneal (P=0.01), and serosal (P=0.03) involvement. CA 72-4 was more frequently positive in patients with lymph node (P=0.01), peritoneal (P=0.03), and liver (P=0.01) involvement. Low 3-year cumulative survival was associated significantly with elevated serum levels of CEA (P=0.001), CA 19-9 (P=0.001), CA 72-4 (P=0.001), and AFP (P=0.01). In multivariate analysis, age, tumor stage, and CA 72-4 were the only independent prognostic factors. Being positive for CA 72-4 was associated with a 3.8-fold higher risk of death (95% confidence intervals: 1.3, 10.9). Conclusion: Our results suggest that high preoperative serum levels of CA 72-4 in gastric cancer patients are associated with a higher risk of death due to gastric cancer.